System Will Be Used in High Throughput Gene Expression And miRNA Service Center

SEATTLE–Rosetta Biosoftware, a global leader in life science informatics solutions, today announced that Phalanx Biotech Group has licensed the Rosetta Resolver® system. Phalanx Biotech Group will integrate the Resolver system into its high throughput OneArray service center for customers who seek whole-genome gene expression and miRNA profiling services. The software system will enable Phalanx to meet the data management and analysis requirements associated with high sample volumes and facilitate collaboration and results sharing between Phalanx and its customers.

“We chose the Resolver system for its ability to support the high throughput gene expression studies and miRNA microarrays that are part of Phalanx Biotech’s OneArray Suite of services as well as its support for compliance of 21 CFR Part 11,” said Dr. Andrew Wang, Chief Executive Officer of Phalanx Biotech. “We are benefiting greatly from the demand for outsourced genomic services, and the Resolver system positions us very well to meet the global demands of our customer base for high-volume sample processing and increased complexity of data analysis across multiple projects.”

“We are pleased that the Phalanx Biotech Group has selected the Rosetta Resolver system,” said Yelena Shevelenko, General Manager, Rosetta Biosoftware. “The Resolver system is ideally suited to handle the data volumes of Phalanx’ state-of-the-art microarray processing center and will enable efficient workflows between Phalanx’ technical support teams and its customers as well as support the collaboration that takes place between Phalanx offices in Taiwan and the United States.”

The Resolver system is in use by premier academic institutions and pharmaceutical companies throughout North America, Europe, and Asia. For more information on the Resolver system, visit www.rosettabio.com/products/resolver. For more information on OneArray services, please call 1-650-320-8669 or email [email protected].

About Phalanx Biotech Group

Founded in 2002, Phalanx Biotech Group is a genomics products company providing research products and services worldwide to genomic researchers. Leveraging world-class, integrated-chip foundry know-how in Taiwan, Phalanx Biotech has applied proprietary inkjet technology to develop and commercialize high-quality, affordable products include OneArray whole genome microarrays, focused gene arrays, and miRNA microarrays. Through its one-stop service center in Taiwan, Phalanx Biotech provides full-service gene expression analysis and miRNA profiling services to the academic, pharmaceutical and biotech communities. As a leader in low-cost microarray production, Phalanx Biotech also offers OEM services for customer microarrays.

Phalanx Biotech has operations in Palo Alto, California and Hsinchu, Taiwan. For more information about Phalanx Biotech, please visit www.phalanxbiotech.com.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Bristol-Myers Squibb, GlaxoSmithKline, Merck & Co., Inc., and Sanofi-Aventis, as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at http://www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Rosetta Elucidator, and Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly-owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics’ technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics’ technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2008 and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver, Resolver, Elucidator, and Syllego are trademarks of Rosetta Inpharmatics LLC.